Adamantane derivatives

Adamantane derivatives
2-Adamantanone,700-58-3,Adamantane derivatives

 

 

 

2-Adamantanone,CAS:700-58-3,>99.0%
2-Adamantanone
2-Adamantanone,700-58-3,Adamantane derivatives
CAS
700-58-3
Molecular Formula
C10H14O
Molecular Weight
150.22
Assay
>99.0%
Appearance
White to off-white crystalline powder
Packing
25kg/Drum;double-bagged, sturdy box
Storage
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Usage
used for Synthesis of pharmaceutical intermediates and photosensitive materials.
Certificate of analysis
700-58-3
View via PDF file
2-Adamantanone,700-58-3,Adamantane derivatives
Specification
Items
Specification
Test result
Appearance
White crystalline powder
White crystalline powder
M.P
283.0-286.0 C
284-284.6
Moisture
N.M.T 0.5%
0.22%
Reside on ignition
N.M.T 0.1%
0.06%
Assay(Dry basis)
N.L.T:99.0%
99.4%
 
Stock status
Purified
85kg In-stock
2016-03-31
Rude
1.2MT In-stock
2016-03-31
Approx 15days from the rude to Purified 2-Adamantanone.
Contact us for more information
Chemical information
Compound Name*
CAS No. "N/A" if the CAS not available*
Quantity*
Contact information
Contact person*
Email Address *
Tel No.*
Company or Organization Name*
Shipping Address*
Country
Remarks

<Privacy policy: the contact information will be only used for this business contact>

Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lanos' Pharmaceutical Co.,LTD ’s product(2-Adamantanone,700-58-3).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.